QuantHealth Secures Strategic Investment from Sanofi Ventures for AI Trial Simulation

QuantHealth, a pioneer in AI-driven clinical trial simulation, has announced a strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment will accelerate QuantHealth's efforts to bring scalable patient-level simulations and digital twin technologies to the forefront of drug development, bringing its total funds raised to $30 million.

The investment comes as Sanofi Ventures continues to expand its deployment following a substantial $625 million multi-year capital commitment from Sanofi announced in October. That commitment increased Sanofi Ventures' total assets under management to over $1.4 billion, reinforcing the pharmaceutical giant's focus on early-stage innovation in immunology, rare diseases, neurology and vaccines. Since its inception in 2012, Sanofi Ventures has deployed over $800 million across more than 70 innovative companies in biotech and digital health.

QuantHealth's platform enables pharmaceutical companies to virtually simulate clinical trials using real-world data and advanced AI models. By generating millions of patient-level digital twins, the platform predicts trial outcomes and optimizes protocol design, aiming to improve trial success rates, timelines and cost efficiency. The platform draws on access to over 350 million patient records combined with proprietary AI algorithms to simulate trials at scale, reduce risk and accelerate development timelines.

The investment has catalyzed an enterprise strategic relationship that supports Sanofi's focus on integrating advanced AI and digital technologies to drive transformation across its research and development ecosystem. As part of the investment, Cris De Luca, Partner at Sanofi Ventures, will join as an observer on QuantHealth's Board of Directors.

"We're proud to welcome Sanofi Ventures as an investor and strategic ally in our journey," said Orr Inbar, CEO and Co-founder of QuantHealth. "Sanofi is at the forefront of digital transformation in pharma, and this relationship will help us scale our impact and bring more predictive, AI-driven approaches to clinical development."

"QuantHealth has the potential to transform how clinical trials are designed and optimized," said Cris De Luca, Partner at Sanofi Ventures. "Their approach to leveraging digital twins and real-world data is advancing the next generation of R&D, and I look forward to supporting the team."

"At Sanofi, we are building an AI-first organization, and engaging with innovators like QuantHealth is central to our strategy," said Emmanuel Frenehard, Chief Digital Officer at Sanofi. "Their platform represents an important opportunity to reimagine clinical trial design through simulation, and we're excited to explore this capability together."

Click here for the original news story.